Eladocagene exuparvovec

艾哌依卡基

Report date: 2024/11/15 10:48:36
First In Class

Base Information

Drug NameEladocagene exuparvovec
Drug Alias NameAAV2-hAADC - Agilis/National Taiwan UniversityAADC deficiency gene therapy programme - AgilisAAV2-hAADC - PTC Therapeutics/National Taiwan UniversityAAV-hAADC-gene-therapy-PTC Therapeutics/National-Taiwan-UniversityAADC deficiency gene therapy programme - PTC Therapeutics +[11] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV2 vector
Mechanisms of ActionDOPA decarboxylase gene transference
TargetsAromatic-L-amino-acid decarboxylase
Therapy Area/IndicationsAromatic amino acid decarboxylase deficiencyAmino Acid Metabolism, Inborn Errors
Global Approved IndicationsAromatic amino acid decarboxylase deficiencyAmino Acid Metabolism, Inborn Errors
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2022/07/18
Country/TerritoryUnited StatesTaiwanUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesNational Taiwan UniversityPtc Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesOrsini Specialty Pharmacy IncNational Taiwan University HospitalPtc Therapeutics Inc +[4] 
Inactive CompaniesN/A
Active IndicationsAromatic amino acid decarboxylase deficiencyAmino Acid Metabolism, Inborn Errors
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A